Metsera, Inc. is a clinical-stage biopharmaceutical company, which is developing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies. The Company uses its proprietary MINT peptide library of nutrient stimulated hormone (NuSH) analog peptides alongside its half-life augmentation by lipid optimization (HALO) half-life extending platform and its MOMENTUM oral NuSH analog peptide delivery platform to deliver differentiated product candidates. Its product pipeline includes MET-097i, MET-233i, MET-233i + MET-097i, MET-097o/MET-224o, MET-002o, MET-034i, MET-067i, and MET-815i. The Company's additional pipeline includes MET-815i, MET-AMYo, MET-034i, MET-067i and MET-PYYi. MET-097i, its advanced product candidate, is a fully biased, monthly, subcutaneously injectable ultra-long acting GLP-1 RA. MET-233i is a subcutaneously injectable ultra-long-acting amylin analog, with enhanced solubility and miscibility with its other NuSH analog peptides.
Símbolo de cotizaciónMTSR
Nombre de la empresaMetsera Inc
Fecha de salida a bolsaJan 31, 2025
Director ejecutivoMr. Christopher Whitten Bernard
Número de empleados74
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 31
Dirección3 World Trade Center
CiudadNEW YORK
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal10007
Teléfono12127846595
Sitio Webhttps://metsera.com/
Símbolo de cotizaciónMTSR
Fecha de salida a bolsaJan 31, 2025
Director ejecutivoMr. Christopher Whitten Bernard
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos